NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Peking University People's Hospital
Conditions: Carcinoma, Endometrioid, Fertility Preservation
Interventions: Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Countries: China
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.
Sex: FEMALE
Age: — to 45 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Endometrioid adenocarcinoma G2, diagnosis by pathological. * The lesion is limited to the endometrium. * FIGO (2009) staging is IA. * Age less than 45. * Strongly request to preserve fertility. * Sign informed consent. Exclusion Criteria: * The tumor has invaded the muscle layer. * FIGO (2009) stage IB or higher. * Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer * There are malignant tumors in other systems. * Have contraindications for conservative treatment or drug use. * Have been judged by the researcher to be unsuitable for childbearing.
- Beijing, Beijing Municipality, China